Literature DB >> 9345088

Laboratory policies and practices for the genetic testing of children: a survey of the Helix network.

D C Wertz1, P R Reilly.   

Abstract

In order to discover whether laboratories have policies regarding the testing of unaffected children, we surveyed all laboratories registered with Helix, a national net-work of DNA diagnostic laboratories. Of 186 laboratories asked to respond anonymously to a four-page questionnaire, 156 (84%) replied. A screening question removed 51 laboratories that provided no clinical services. Of the remaining 105, 92% said that their requisition forms asked the person's age. Substantial minorities had policies for the testing of minors for late-onset disorders (46%), for carrier status for recessive disorders (33%), or for disorders for which the test offers no medical benefit within 3 years (33%). Most laboratories are responsive to parental requests. For 12 of 13 late-onset disorders, the majority of laboratories that offered testing had had requests to test children. The majority had tested healthy children, <12 years of age, for eight disorders. Approximately 22% had tested children, <12 years of age, for Huntington disease. Majorities had received requests to test healthy children for carrier status for 10 of 15 recessive or X-linked disorders and had tested children, <12 years of age, for 6 of these disorders, including cystic fibrosis, hemophilia A, fragile X syndrome, and Duchenne muscular dystrophy. Approximately 45% of the laboratories occasionally had provided tests directly to consumers. In view of the possibility that the harms of presymptomatic diagnoses of children sometimes may outweigh the benefits, our results suggest a need for consistent laboratory policies designed for the best interests of the child and the family.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  1997        PMID: 9345088      PMCID: PMC1716052          DOI: 10.1086/301593

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Should we test children for "adult" genetic diseases?

Authors:  P S Harper; A Clarke
Journal:  Lancet       Date:  1990-05-19       Impact factor: 79.321

2.  A private view of heterozygosity: eight-year follow-up study on carriers of the Tay-Sachs gene detected by high school screening in Montreal.

Authors:  S Zeesman; C L Clow; L Cartier; C R Scriver
Journal:  Am J Med Genet       Date:  1984-08

3.  The adolescent copes with genetic screening: a study of Tay-Sachs screening among high-school students.

Authors:  C L Clow; C R Scriver
Journal:  Prog Clin Biol Res       Date:  1977

4.  Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology.

Authors:  L Went
Journal:  J Med Genet       Date:  1990-01       Impact factor: 6.318

5.  Opinion: predictive testing for Huntington disease in childhood: challenges and implications.

Authors:  M Bloch; M R Hayden
Journal:  Am J Hum Genet       Date:  1990-01       Impact factor: 11.025

6.  Presymptomatic direct detection of adenomatous polyposis coli (APC) gene mutations in familial adenomatous polyposis.

Authors:  G M Petersen; C Francomano; K Kinzler; Y Nakamura
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

7.  Genetic testing for children and adolescents. Who decides?

Authors:  D C Wertz; J H Fanos; P R Reilly
Journal:  JAMA       Date:  1994-09-21       Impact factor: 56.272

  7 in total
  3 in total

1.  Guidelines for genetic testing of healthy children.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

2.  Predictive genetic testing in children and adults: a study of emotional impact.

Authors:  S Michie; M Bobrow; T M Marteau
Journal:  J Med Genet       Date:  2001-08       Impact factor: 6.318

3.  Experience, knowledge, and opinions about childhood genetic testing in Batten disease.

Authors:  Heather R Adams; Katherine Rose; Erika F Augustine; Jennifer M Kwon; Elisabeth A deBlieck; Frederick J Marshall; Amy Vierhile; Jonathan W Mink; Martha A Nance
Journal:  Mol Genet Metab       Date:  2013-11-04       Impact factor: 4.797

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.